Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, pursuant to a merger agreement dated September 10, 2026. Veracyte paid $150 million in aggregate cash consideration to Convergent securityholders, with potential additional payments of up to $30 million based on specified milestones related to UroAmp publications and reimbursement efforts. The acquisition adds Convergent’s UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio, targeting non-muscle invasive bladder cancer care. Veracyte expects to commercialize the initial test in late 2028. Veracyte is a global diagnostics company that uses molecular tests to assess tumor biology and guide cancer care decisions.
